Gilead Sciences (GILD) Announces Kite’s Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of … – StreetInsider.com
|
Gilead Sciences (GILD) Announces Kite's Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of …
StreetInsider.com Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment … |
